|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Real estate properties: | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Buildings, building improvements and intangible assets | ||||||||||||||||||||
| Buildings, improvements and intangibles | ||||||||||||||||||||
| Construction in progress | ||||||||||||||||||||
| Real estate properties, gross | ||||||||||||||||||||
| Total real estate properties | ||||||||||||||||||||
| Less: Accumulated depreciation and amortization | ||||||||||||||||||||
| Total real estate properties, net | ||||||||||||||||||||
| Mortgage and other notes receivable, net of credit loss reserve of $15,397 and $15,397, respectively | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Straight-line rents receivable | ||||||||||||||||||||
| Assets held for sale, net | ||||||||||||||||||||
| Other assets, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity: | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Debt, net | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Deferred income | ||||||||||||||||||||
| Deferred income tax liabilities, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interest | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Capital in excess of par value | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Cumulative dividends | ||||||||||||||||||||
| Total National Health Investors, Inc. stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Common stock, shares issued (in shares) | ||||||||||||||||||||
Loading...
